MarketBeat provided consensus price targets and ratings, while DBV Technologies and XTL Biopharmaceuticals compete in the small-cap healthcare market.
1 report, 1 independent
Updated Sep 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat provided consensus price targets and ratings, while DBV Technologies and XTL Biopharmaceuticals compete in the small-cap healthcare market.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
MarketBeat
American personal finance blog
-
DBV Technologies
publicly owned French biopharmaceutical firm headquartered in Bagneux, France
Nothing else this week.
Related events
- MarketBeat provided consensus price targets and ratings for Liquidia and Ovid Therapeutics.
- MarketBeat is reporting on analyst recommendations and consensus target prices for small-cap healthcare companies Myriad Genetics and Applied DNA Sciences.
- MarketBeat reported consensus price targets and analyst ratings for TScan Therapeutics and Mereo BioPharma Group.
- MarketBeat provided analyst ratings and targets for small-cap healthcare companies Emergent BioSolutions and Entrada Therapeutics.
- MarketBeat has released its consensus rating and target price for Sunshine Biopharma, Inc.